D. Sonnichsen

发表

J. Humphrey, K. Price, E. Gupta, 2003 .

Effects of Ketoconazole on the Pharmacokinetics of Ponatinib in Healthy Subjects

F. Haluska, D. Dorer, D. Sonnichsen, 2013, Journal of clinical pharmacology.

Evaluation of the effect of multiple doses of rifampin on the pharmacokinetics and safety of ponatinib in healthy subjects

D. Dorer, D. Sonnichsen, N. Narasimhan, 2015, Clinical pharmacology in drug development.

A Review and Assessment of Potential Sources of Ethnic Differences in Drug Responsiveness

T. Bjornsson, J. Wagner, D. Sonnichsen, 2003, Journal of clinical pharmacology.

Ascending single-dose study of the safety profile, tolerability, and pharmacokinetics of bosutinib coadministered with ketoconazole to healthy adult subjects.

D. Sonnichsen, R. Abbas, S. Chalon, 2012, Clinical therapeutics.

A randomized, crossover, placebo‐ and moxifloxacin‐controlled study to evaluate the effects of bosutinib (SKI‐606), a dual Src/Abl tyrosine kinase inhibitor, on cardiac repolarization in healthy adult subjects

B. Hug, D. Sonnichsen, R. Abbas, 2012, International journal of cancer.

A Single-Dose, Crossover, Placebo- and Moxifloxacin-Controlled Study to Assess the Effects of Neratinib (HKI-272) on Cardiac Repolarization in Healthy Adult Subjects

B. Hug, D. Sonnichsen, R. Abbas, 2010, Clinical Cancer Research.

Evaluation of the Effect of Multiple Doses of Lansoprazole on the Pharmacokinetics and Safety of Ponatinib in Healthy Subjects

D. Dorer, D. Sonnichsen, N. Narasimhan, 2014, Clinical Drug Investigation.

Effect of Ketoconazole on the Pharmacokinetics of Oral Bosutinib in Healthy Subjects

B. Hug, D. Sonnichsen, R. Abbas, 2011, Journal of clinical pharmacology.

Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five days.

T. Fojo, S. Bates, A. Rutt, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bioavailability and phase II study of oral UFT plus leucovorin in patients with relapsed or refractory colorectal cancer

N. Meropol, D. Sonnichsen, I. Ferreira, 1999, Cancer Chemotherapy and Pharmacology.

Bioavailability and phase II study of oral UFT plus leucovorin in patients with relapsed or refractory colorectal cancer

N. Meropol, D. Sonnichsen, I. Ferreira, 1997, Cancer Chemotherapy and Pharmacology.

Evaluation of pharmacokinetics and safety of ponatinib in subjects with chronic hepatic impairment and matched healthy subjects

D. Dorer, T. Marbury, D. Sonnichsen, 2014, Cancer Chemotherapy and Pharmacology.

Phase I Biodistribution and Pharmacokinetic Study of Lewis Y–Targeting Immunoconjugate CMD-193 in Patients with Advanced Epithelial Cancers

A. Scott, M. Brechbiel, N. Tebbutt, 2009, Clinical Cancer Research.

A double-blind, randomized, multiple-dose, parallel-group study to characterize the occurrence of diarrhea following two different dosing regimens of neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor

B. Hug, D. Sonnichsen, R. Abbas, 2012, Cancer Chemotherapy and Pharmacology.

Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects.

B. Hug, D. Sonnichsen, R. Abbas, 2011, British journal of clinical pharmacology.

Intravenous temsirolimus in cancer patients: clinical pharmacology and dosing considerations.

B. Hug, J. Boni, D. Sonnichsen, 2009, Seminars in oncology.

A single-dose placebo- and moxifloxacin-controlled study of the effects of temsirolimus on cardiac repolarization in healthy adults

B. Hug, J. Boni, D. Sonnichsen, 2012, Cancer Chemotherapy and Pharmacology.

Effect of rifampin on the pharmacokinetics of bosutinib, a dual Src/Abl tyrosine kinase inhibitor, when administered concomitantly to healthy subjects

J. Boni, D. Sonnichsen, R. Abbas, 2015, Drug metabolism and personalized therapy.

Phase I T rial a nd P harmacokinetic S tudy o f B MS-247550, a n Epothilone B A nalog, A dministered I ntravenously o n a D aily Schedule f or F ive D ays

T. Fojo, S. Bates, A. Rutt, 2003 .

Analysis of the potential effect of ponatinib on the QTc interval in patients with refractory hematological malignancies

I. Flinn, H. Kantarjian, F. Haluska, 2011, Cancer Chemotherapy and Pharmacology.

A Phase I Study of Oral BMS-275291, a Novel Nonhydroxamate Sheddase-Sparing Matrix Metalloproteinase Inhibitor, in Patients with Advanced or Metastatic Cancer

J. Marshall, H. Hurwitz, N. Rizvi, 2004, Clinical Cancer Research.

Validation of the pharmacodynamics of BMS-247550, an analogue of epothilone B, during a phase I clinical study.

S. Mani, F. Muggia, D. Sonnichsen, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

A Clinical Study to Examine the Potential Effect of Lansoprazole on the Pharmacokinetics of Bosutinib when Administered Concomitantly to Healthy Subjects

D. Sonnichsen, R. Abbas, C. Leister, 2013, Clinical Drug Investigation.

Evaluation of the pharmacokinetics and safety of bosutinib in patients with chronic hepatic impairment and matched healthy subjects

D. Sonnichsen, R. Abbas, S. Chalon, 2012, Cancer Chemotherapy and Pharmacology.

A phase I ascending single-dose study of the safety, tolerability, and pharmacokinetics of bosutinib (SKI-606) in healthy adult subjects

B. Hug, D. Sonnichsen, R. Abbas, 2011, Cancer Chemotherapy and Pharmacology.

Effect of Futibatinib on Cardiac Repolarization: Results of a Randomized, Controlled, Double‐Blind, QT/QTc, Phase 1 Study in Healthy Subjects

D. Sonnichsen, K. Benhadji, R. Lester, 2022, Clinical pharmacology in drug development.

The Effect of a High‐Fat Meal on the Pharmacokinetics of Brigatinib, an Oral Anaplastic Lymphoma Kinase Inhibitor, in Healthy Volunteers

K. Venkatakrishnan, D. Dorer, D. Sonnichsen, 2018, Clinical pharmacology in drug development.

Effect of food on the oral bioavailability of UFT and leucovorin in cancer patients.

R. Pazdur, F. Ravandi, D. Alberts, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Clinically Significant Cytochrome P‐450 Drug Interactions—A Comment

D. Sonnichsen, N. Ford, D. Sonnichsen, 1998, Pharmacotherapy.

Clinical Pharmacokinetics of Paclitaxel

M. Relling, D. Sonnichsen, 1994, Clinical pharmacokinetics.

Effects of food on the pharmacokinetics of ponatinib in healthy subjects

F. Haluska, D. Sonnichsen, K. Niland, 2013, Journal of clinical pharmacy and therapeutics.

Phase I clinical trial of the farnesyltransferase inhibitor BMS-214662 administered as a weekly 24 h continuous intravenous infusion in patients with advanced solid tumors

Jeffrey W. Clark, A. Zhu, D. Ryan, 2006, Cancer Chemotherapy and Pharmacology.

Pharmacokinetics and pharmacodynamics of 21‐day continuous oral etoposide in pediatric patients with solid tumors

M. Relling, D. Sonnichsen, P. Mathew, 1995, Clinical pharmacology and therapeutics.

Cancer Drug Discovery and Development

J. Humphrey, K. Price, E. Gupta, 2002 .

mTOR inhibition following a single intravenous infusion of temsirolimus in healthy individuals

B. Hug, J. Boni, D. Sonnichsen, 2007 .

Effects of Strong CYP2C8 or CYP3A Inhibition and CYP3A Induction on the Pharmacokinetics of Brigatinib, an Oral Anaplastic Lymphoma Kinase Inhibitor, in Healthy Volunteers

K. Venkatakrishnan, D. Dorer, D. Sonnichsen, 2019, Clinical pharmacology in drug development.

Evaluation of the Mass Balance and Metabolic Profile of Futibatinib in Healthy Participants

D. Sonnichsen, K. Benhadji, Yaohua He, 2023, Clinical pharmacology in drug development.

Evaluation of Potential Food Effects and Drug Interactions With Lansoprazole in Healthy Adult Volunteers Receiving Futibatinib

D. Sonnichsen, K. Benhadji, A. Hunt, 2022, Clinical pharmacology in drug development.